Cemiplimab for locally advanced and metastatic basal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2043748
Abstract: ABSTRACT Introduction Locally advanced basal cell carcinoma (laBCC) represents approximatively 1% of all BCCs. Metastatic BCC (mBCC) is even more rare. Most cases are observed in immunocompromised patients, particularly solid organ transplant recipients (OTRs). When… read more here.
Keywords: labcc mbcc; therapy; cemiplimab; cell ... See more keywords